CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cadent
Therapeutics, a company focused on the development of therapies to
improve the lives of patients with movement and cognitive disorders,
today announced that Jodie Morrison, the Company’s Chief Executive
Officer, will present at the Jefferies Healthcare Conference on Tuesday,
June 4, 2019 at 10:00 am ET in New York City.
About Cadent Therapeutics
Cadent Therapeutics is creating breakthrough therapies for the treatment
of movement disorders and cognitive impairment. The company combines
target specificity, patient selection, drug design and optimization, and
novel quantitative endpoints to create first-in-class molecules to treat
movement and cognitive disorders. Cadent Therapeutics is rapidly
advancing its pipeline of positive allosteric modulators to treat
spinocerebellar ataxia, essential tremor and schizophrenia. The company
has an exclusive license and collaboration agreement with Novartis to
develop a negative allosteric modulator, now in Phase 1 clinical studies
for the treatment of treatment resistant depression. Investors include
Atlas Venture, Cowen Healthcare Investments, Qiming Venture Partners,
Access Industries, Clal Biotechnology Industries, Novartis Institutes
for Biomedical Research and Slater Technology Fund. For more
information, please visit cadenttx.com.
Contacts
Investors:
Maeve Conneighton, maeve@argotpartners.com
212.600.1902
Media:
David
Rosen, david.rosen@argotpartners.com
212.600.1902